BUSINESS
Concord Biotech Bonus Leaves Jhunjhunwala Trusts Holding 24%
Concord Biotech’s 1:1 bonus halved the screen price on November 4, while Jhunjhunwala children’s trusts still hold 24.09% of the API maker.
Concord Biotech opened at Rs 610 on November 4 after a Rs 1,229.90 close, a print some apps read as a 50% crash. The stock had turned ex-bonus for a 1:1 issue that doubles every eligible holding. Three trusts for the children of the late Rakesh Jhunjhunwala still own 24.09% of the Ahmedabad drugmaker.
That percentage does not change when the share count doubles. The stock is still 23% below its adjusted August high of Rs 807.03.
Why Concord Biotech Shares Look 50% Cheaper?
Concord Biotech Ltd settled at Rs 1,229.90 on Tuesday, November 3, then opened at Rs 610 on Wednesday, November 4, once the 1:1 bonus went ex. Half of Tuesday’s close is Rs 614.95, so the open was a small discount to the theoretical ex-price, not a collapse in the company’s value. Some broker apps still showed Tuesday’s unadjusted close beside Wednesday’s new price and painted a 50% to 52% fall.
Early trade printed Rs 595, then the stock bounced 4.8% to Rs 623.65. At that price the company was worth about Rs 13,050 crore on 20,92,32,408 shares. Trading desks treated the session as a scheduled ex-bonus print. The panic lived on phone screens that had not lined up the old close with the new face value of the holding.
THE WEDNESDAY TAPE
- Tuesday close: Rs 1,229.90 on November 3, before the bonus adjustment.
- Wednesday open: Rs 610 on November 4, against a theoretical half of Rs 614.95.
- Session low: Rs 595 in early trade, the weakest tick after the adjustment.
- Rebound print: Rs 623.65, up 4.8% from the low, for a market value near Rs 13,050 crore.
A holder who owned 100 shares at Rs 1,229.90 still owned the same economic slice after the bonus: 200 shares near Rs 615. The receipt of the extra shares is not taxed when they land in a demat account. Indian tax rules treat the cost of bonus shares as nil, so capital gains tax applies only when those extra shares are sold, and the holding period starts on the allotment date.

Concord’s First Bonus Doubles the Share Count
This is the first bonus in Concord’s listed life. The board approved a 1:1 issue on September 23, 2026, taking Rs 10.46 crore from the share premium account, which held Rs 81.97 crore as of March 31, 2026. Paid-up capital rises from Rs 10.46 crore to Rs 20.92 crore, and authorised capital was lifted from Rs 11 crore to Rs 22 crore so the new shares would fit. Company secretary Paritosh Trivedi told the exchanges the board had fixed November 4 as the record date, with Thursday, November 5 as the deemed allotment date.
BSE told members the scrip (543960) would trade ex-bonus from November 4 in settlement DR-749/2026-2027, and that the company would allot 10,46,16,204 bonus equity shares of Re 1 each, one for every share held. NSE lists the stock as CONCORDBIO. Face value stays Re 1. No cash leaves the company, and no holder’s percentage moves.
THE BONUS IN FIGURES
| Item | Detail |
|---|---|
| Ratio | 1 bonus share for every 1 share held |
| Record date and ex-date | November 4, 2026 |
| Deemed allotment | November 5, 2026 |
| New shares | 10,46,16,204 of Re 1 each |
| Paid-up capital | Rs 10.46 crore to Rs 20.92 crore |
| Share premium used | Rs 10.46 crore of Rs 81.97 crore |
The calendar sat next to a clean US regulatory print. On September 18, five days before the bonus vote, Concord said the US Food and Drug Administration had finished an inspection at Unit II, the formulation plant at Valthera in Dholka taluka, with one minor procedural observation that was not related to good manufacturing practice. Trivedi wrote that the company did not expect any material impact on operations or supplies from that site.
FROM INSPECTION TO ALLOTMENT
- September 18, 2026: USFDA closes the Valthera inspection with one minor procedural observation.
- September 23, 2026: Board approves the maiden 1:1 bonus and the rise in authorised capital to Rs 22 crore.
- October 27, 2026: Board fixes November 4 as the record date and November 5 as deemed allotment.
- November 4, 2026: Stock trades ex-bonus; some apps still show the unadjusted Tuesday close.
- November 5, 2026: Company allots 10,46,16,204 new shares.
A lower rupee price is the point of a 1:1 bonus for a stock that had been changing hands above Rs 1,200. More shares in the market can thicken the book. They do not add a rupee of sales or cash.
Three Children’s Trusts Still Hold 24.09%
The reason Concord is still sold as a Jhunjhunwala name sits in the public shareholding, not in the promoter box. Sudhir Vaid, chairman and managing director, and Ankur Vaid, joint managing director and chief executive, lead a promoter group that held 44.08% as of the June quarter. The Jhunjhunwala block is classified as public. It has not been sold since the August 2023 listing.
Rakesh Jhunjhunwala and his wife Rekha put money into the company in 2004. After he died on August 14, 2022, the holding moved into three discretionary trusts named for their children, the twins Aryaman and Aryavir and their daughter Nishtha. Each trust holds 8.03%. Together they own 2,51,99,240 shares, or 24.09%. After the bonus that count becomes 5,03,98,480 shares. The percentage is the same. At Rs 623.65 the block is worth about Rs 3,143 crore.
THE THREE TRUSTS
- Aryaman Jhunjhunwala Discretionary Trust: 83,99,754 shares, 8.03%, doubling to 1,67,99,508 shares.
- Aryavir Jhunjhunwala Discretionary Trust: 83,99,754 shares, 8.03%, doubling to 1,67,99,508 shares.
- Nishtha Jhunjhunwala Discretionary Trust: 83,99,732 shares, 8.03%, doubling to 1,67,99,464 shares.
Small retail holders are the group that meets a halved price on a phone. About 79,000 holders with authorised capital up to Rs 2 lakh owned 7.03% at the end of the June quarter. Their screens are where an unadjusted close turns a bonus into a crash alert. The trusts do not need that alert. They have sat on the same 24.09% through listing, through a 2025 drawdown, and through this bonus.
September Sales Grew Faster Than Profit
Concord is an R&D-led maker of fermentation-based APIs and formulations, with more than 30 such APIs, four plants in Gujarat, and customers in more than 70 countries. The listed entity dates to an August 18, 2023 debut. The operating company was incorporated in 1984 and rebuilt from 2000 under Sudhir Vaid, a microbiologist who had run biotechnology at Ranbaxy, on a Dholka site that had been a chemical plant.
Unaudited results for the quarter ended September 30, 2026 show consolidated revenue from operations of Rs 309.07 crore (30,907.02 lakhs), up 25.1% from Rs 247.06 crore a year earlier and up 20.0% from Rs 257.49 crore in the June quarter. Consolidated net profit was Rs 69.57 crore, up 10.3% from Rs 63.06 crore. Profit attributable to owners was Rs 70.65 crore, a separate line because the minority and joint-venture slice ran negative. Basic earnings per share were Rs 6.65, against Rs 6.03 a year earlier, on a Re 1 face value and before the bonus adjustment to the share count.
Q2 FY27 VERSUS Q2 FY26
| Line | Q2 FY27 | Change |
|---|---|---|
| Revenue from operations | Rs 309.07 crore | +25.1% year on year |
| Consolidated net profit | Rs 69.57 crore | +10.3% year on year |
| Profit to owners | Rs 70.65 crore | Separate from consol PAT |
| EBITDA | Rs 104.4 crore | +18%, margin 33.8% vs 35.8% |
| Gross margin | 76.2% | Down from 80.2% |
| API sales | Rs 250.1 crore | +30% |
| Formulation sales | Rs 58.9 crore | +6% |
API did the lifting. Management told analysts oncology almost doubled and immunosuppressants grew at a high double-digit rate, with domestic API up 42% and domestic formulations up 29%, while exports excluding deemed exports rose 8%. Gross margin shrank about 400 basis points on costlier solvents and mix. EBITDA rose 18% to Rs 104.4 crore, but the margin slipped to 33.8% from 35.8%. Concord said the margin would have been 37.1% if costs of the new injectables unit and US front-end unit Stellon Biotech were set aside. Cash and cash equivalents were about Rs 445 crore on September 30, 2026, with no debt.
For the first half, revenue was Rs 566.56 crore and consolidated net profit Rs 127.27 crore. On the same call the company pointed to ANDA approvals for tofacitinib and mycophenolate mofetil oral suspension and to the launch of Inspira, a dermatology line. Full-year FY26 revenue was Rs 1,054.89 crore with net profit of Rs 259.23 crore. Management said FY27 growth should run a little above the historical 18% to 19% range, with EBITDA margins moving toward 38% to 40% over the medium term as Stellon and injectables ramp. Those targets sit above the 33.8% printed in the September quarter.
A 15-Minute Call in Ahmedabad in 2004
The trusts are a 22-year position, not a trading lot. Equity manager Ravi Dharamshi, who was on the 2004 trip, has said Jhunjhunwala took a quarter of an hour to decide after they flew down to Ahmedabad for that meeting with Sudhir Vaid, when Concord was still a small fermentation shop.
Time taken by Shri Rakesh Jhunjhunwala to decide on Investment: 15 minutes (we literally flew down to Ahmedabad for that).
Ravi Dharamshi, equity portfolio manager, on X
Utpal Sheth, who helps run Rare Enterprises, has described the logic as a bet on drugs patients cannot switch. Bulk of the revenue, he said, came from immunosuppressants, medicines where a patient cannot simply move to another brand of the same molecule, a chronic, lifelong business the firm judged more valuable than most other pharmaceutical products, paired with a clean FDA record and low costs.
That product list is still the core. Concord’s API page names tacrolimus, cyclosporine and sirolimus among the immunosuppressants, with oncology names such as everolimus and doxorubicin and a string of anti-infectives. The 2023 IPO did not raise primary cash for the company. It was an offer for sale of about 2.09 crore shares by Helix Investment Holdings, backed by Quadria Capital, at Rs 741, raising Rs 1,550.52 crore and taking Helix out of a 20% stake. The stock listed on August 18, 2023 at Rs 900, a 21.5% premium. Promoters stayed at 44.08%. The three trusts stayed at 24.09%. At Rs 623.65, the bonus-adjusted IPO price of Rs 370.50 is 68% below the market, which is another way of saying the listing-day buyers who never sold are still ahead, and the buyers who paid the August 2026 high are not.
The August Peak Is Still 23% Away
Strip out the app glitch and Concord is a stock that has already given back about a quarter of its adjusted 52-week high of Rs 807.03, hit in August 2026. It is 26% above the adjusted 52-week low of Rs 493.53 from April 2026. A 1:1 bonus does not close that gap. It only restates it on twice as many shares.
WHAT THE BONUS DOES NOT CHANGE
- The family percentage: The three trusts remain at 24.09% after 5,03,98,480 shares replace 2,51,99,240.
- The promoter block: Sudhir Vaid and Ankur Vaid’s group stays at 44.08% of a larger share count.
- The September P&L: Sales still grew 25.1% while consolidated profit grew 10.3%, with EBITDA margin at 33.8%.
- The August high: Rs 807.03 on an adjusted basis is still 23% above the Rs 623.65 rebound print.
What does change is the rupee handle and the number of shares the trusts, the Vaids, and those 79,000 small holders can sell. A name that quoted above Rs 1,200 now quotes in the Rs 600s. Liquidity can improve because the lot is cheaper. The three children’s trusts, sitting on a position first taken when Concord was a private Ahmedabad fermentation plant, will be allotted their extra shares on November 5 and will still own 24.09% of the company.
Disclaimer: This article is news reporting and analysis of Concord Biotech’s bonus issue, shareholding and published results, and is for information only. It is not investment advice, a research report, a buy or sell recommendation, or a solicitation to deal in Concord Biotech or any other security. Readers should consult a SEBI-registered investment adviser or a qualified financial planner who can look at their own holdings, tax status and risk limits before they act. Share prices, market values, bonus credit dates and financial figures reflect the exchange filings and market prints cited here as of November 4, 2026 and can change in the next session.
NEWS2 months agoClancy Juror Says the Holdout Never Cited Evidence
NEWS3 months agoThe iPhone 18 Pro Max Splits Apple’s Fall in Two
NEWS3 months agoOpenAI Calls GPT-6 Astra AGI Then Locks Its Exploits
BUSINESS3 months agoTrump Claims Hormuz Control as Oil Holds Near $96
LIFESTYLE3 months agoRussia Closes the Goethe-Institut Berlin Tried to Save
AUTO3 months agoVolkswagen’s Job Cuts Leave Four Plants Without Cars
NEWS3 months agoDyson Puts Nurovi Robots on Sale Without the UV Flagship
BUSINESS2 months agoUS Destroys Five Iranian Tankers as the Shock Hits Jordan













